Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

21 Sept 2016

Abstract excerpt

Approximately 20% of HER2 positive breast cancer develops disease recurrence after adjuvant trastuzumab treatment. This study aimed to develop a molecular prognostic model that can reliably stratify patients by risk of developing disease recurrence. Using miRNA microarrays, nine miRNAs that differentially expressed between the recurrent and non-recurrent patients were identified. Then, we validated the expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cell Adhesion Molecules Research
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27650797
DOI: 10.1038/srep33825

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatmentPMID 27650797Read ↗

Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast CancerSemantic proximity Read ↗

Comparison of time-varying recurrence patterns in breast cancer patients with different molecular subtypes treated from 2008 to 2012 and from 2013 to 2016: a single-center retrospective studySemantic proximity Read ↗

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read ↗

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal CancerSemantic proximity Read ↗

Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in HER2-positive early breast cancerSemantic proximity Read ↗

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

A microRNA Signature Associated with Early Recurrence in Breast CancerSemantic proximity Read ↗

Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerSemantic proximity Read ↗

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of RecurrenceSemantic proximity Read ↗

Breast cancer lncRNA-microRNA categories: new targets for therapeutic interventionSemantic proximity Read ↗

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG StudySemantic proximity Read ↗

RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.